Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Johnson and Johnson
McKinsey
Colorcon
Chubb
Fuji
Federal Trade Commission
Daiichi Sankyo
UBS
Citi

Generated: June 24, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,680,103

« Back to Dashboard

Which drugs does patent 8,680,103 protect, and when does it expire?

Patent 8,680,103 protects SPRYCEL and is included in one NDA.

This patent has forty-two patent family members in twenty-seven countries.
Summary for Patent: 8,680,103
Title:Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors
Abstract: The invention relates to a pharmaceutical composition of a crystalline monohydrate of the compound of formula (IV) ##STR00001## wherein the crystalline monohydrate is characterized by certain unit cell parameters.
Inventor(s): Lajeunesse; Jean (Candiac, CA), DiMarco; John D. (East Brunswick, NJ), Galella; Michael (Kendall Park, NJ), Chidambaram; Ramakrishnan (Santa Clara, CA)
Assignee: Bristol-Myers Squibb Company (Princeton, NJ)
Application Number:13/562,399
Patent Claim Types:
see list of patent claims
Composition; Compound;

Drugs Protected by US Patent 8,680,103

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Bristol Myers Squibb SPRYCEL dasatinib TABLET;ORAL 021986-001 Jun 28, 2006 AB RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Bristol Myers Squibb SPRYCEL dasatinib TABLET;ORAL 021986-002 Jun 28, 2006 AB RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Bristol Myers Squibb SPRYCEL dasatinib TABLET;ORAL 021986-003 Jun 28, 2006 AB RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Bristol Myers Squibb SPRYCEL dasatinib TABLET;ORAL 021986-005 Oct 28, 2010 RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 8,680,103

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,491,725 Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors ➤ Try a Free Trial
8,242,270 Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Family Members for US Patent 8,680,103

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Taiwan 200628156 ➤ Try a Free Trial
Taiwan I338004 ➤ Try a Free Trial
Taiwan 200530205 ➤ Try a Free Trial
Slovenia 1711481 ➤ Try a Free Trial
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Healthtrust
McKesson
McKinsey
Queensland Health
Cipla
Cerilliant
Deloitte
Julphar
UBS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.